Prelude Therapeutics Inc Stock Price, News & Analysis

Prelude Therapeutics (Nasdaq: PRLD) recently announced promising data from its Phase 1 trials of oral PRMT5 inhibitors PRT543 and PRT811, which showed favorable safety profiles and preliminary clinical activity with durable responses in various tumors. Specifically, PRT543 achieved a 69% reduction in serum sDMA and demonstrated a durable complete response in a patient with HRD+ ovarian cancer. PRT811 exhibited an 83% reduction in serum sDMA, with notable responses in patients with high-grade gliomas and uveal melanoma. Additionally, preclinical studies indicated PRT2527's efficacy in hematological malignancies.

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology firm, announced its participation in two virtual investor conferences. The first will be at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:45 a.m. ET, featuring a fireside chat. The second event is at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, with a corporate presentation. Live webcasts are available on the company's website and will be replayed for a limited time.

Prelude Therapeutics (Nasdaq: PRLD) reported a net loss of $26.9M for Q2 2021, equating to $0.58 per share, a significant increase from a net loss of $11.4M, or $5.50 per share, in Q2 2020. The company has $343.1M in cash for ongoing clinical trials, including Phase 1 studies of PRT543, PRT811, and PRT1419. Upcoming milestones include data presentations at the AACR-NCI-EORTC Annual Meeting. R&D expenses rose to $22.4M, driven by increased clinical research costs, while G&A expenses rose to $5.5M due to personnel growth and professional fees.

Prelude Therapeutics (Nasdaq: PRLD) appointed Martin Babler to its Board of Directors, bringing over 25 years of biotech experience, including his role as CEO of Principia Biopharma until its acquisition in 2020. Mr. Babler will also serve on the Audit Committee. CEO Kris Vaddi emphasized the value of his expertise in driving the company's pipeline of cancer therapies. Prelude focuses on precision oncology, with candidates like PRT543 and PRT811 in clinical trials targeting significant cancer unmet needs.

Prelude Therapeutics (Nasdaq: PRLD) announced participation in two virtual investor conferences: the 42nd Annual Goldman Sachs Global Healthcare Conference with a fireside chat on June 9, 2021, at 8:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays for a limited time. Prelude focuses on precision oncology with notable candidates like PRT543 for advanced solid tumors and PRT811 for glioblastoma.

Prelude Therapeutics (Nasdaq: PRLD) announced its Q1 2021 financial results and provided updates on clinical trials. Key developments include enrollment in multiple expansion cohorts for PRT543, a PRMT5 inhibitor, and ongoing dose escalation in PRT1419, an MCL1 inhibitor. Initial clinical data for PRT543 and PRT811 is expected in 2H21. As of March 31, 2021, the company reported $363 million in cash, with a net loss of $21.3 million or $0.47 per share. R&D expenses rose to $16.5 million. The company anticipates sufficient funds to support operations into 2023.

Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), has announced that CEO Kris Vaddi, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 p.m. ET. The presentation will be available via live webcast on the Company’s investor website, with a replay accessible later.

Prelude is developing innovative oral drug candidates for critical cancer pathways, including PRT543 and PRT811, both in Phase 1 trials targeting advanced tumors and glioblastoma. Their pipeline also includes PRT1419, a promising MCL1 inhibitor.

Prelude Therapeutics (Nasdaq: PRLD) reported its financial results for Q4 and full year 2020, highlighting a net loss of $19.3 million for Q4 and $56.9 million for the year. The company completed the dose escalation of its lead product PRT543 and plans to start expansion cohorts in Q2 2021. Prelude also announced ongoing trials for PRT1419 and PRT811, with anticipated data readouts in 2H21. The successful public offering raised $172.5 million, and cash reserves of $218.3 million are expected to support operations into 2023.

Prelude Therapeutics (Nasdaq: PRLD) announced management participation in three virtual investor conferences. Key details include:

• Barclays Global Healthcare Conference: March 10, 2021, at 8:35 a.m. ET.
• Morgan Stanley Virtual Healthcare Corporate Access Day: One-on-one meetings on March 16, 2021.
• Oppenheimer 31st Annual Healthcare Conference: March 17, 2021, at 3:50 p.m. ET.

Webcasts available on the company's website, where replays will also be accessible.